Related Experiment Video
Updated: Feb 10, 2026

Measurement of Specific Mycobacterial Mistranslation Rates with Gain-of-function Reporter Systems
Published on: April 26, 2019
Case Report: Treatment of systemic mastocytosis with sunitinib
Gerhard J Molderings1, Lawrence B Afrin2, Hans-Jörg Hertfelder3
1Institute of Human Genetics, University Hospital Bonn, Bonn, D-53127, Germany.
Abstract:
Mast cell activation disease typically presents as chronic multisystem polymorbidity of generally inflammatory ± allergic theme. Presently, treatment of the rare, cytoproliferative variant systemic mastocytosis employs empirically selected therapies to impede mast cell mediator production and action and, when necessary, inhibition of proliferation. Some tyrosine kinase inhibitors (TKIs) have been used successfully in uncommon cases of systemic mastocytosis not bearing that disease's usual imatinib-resistant KIT D816V mutation. Recently, sunitinib, a multi-targeted TKI, had been successful in a case of systemic mast cell activation syndrome. In addition, most allergy is principally a mast cell activation phenomenon, and sunitinib has been shown helpful in controlling a murine model of oral allergy syndrome. Here, we present the first use of sunitinib in systemic mastocytosis.
Insights
Sunitinib, a targeted therapy, shows promise for treating systemic mastocytosis, a rare disorder. This study reports the first successful use of sunitinib in a systemic mastocytosis patient, offering new hope for managing this condition.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Mast cell activation disease is a chronic, multisystem inflammatory condition.
- Systemic mastocytosis, a rare variant, involves mast cell proliferation and mediator release.
- Current treatments for systemic mastocytosis are empirical, targeting mediator production or proliferation.
Purpose of the Study:
- To evaluate the efficacy of sunitinib, a multi-targeted tyrosine kinase inhibitor (TKI), in a patient with systemic mastocytosis.
- To assess sunitinib's potential in managing mast cell activation and proliferation in systemic mastocytosis.
Main Methods:
- Case report of the first use of sunitinib in systemic mastocytosis.
- Sunitinib, a multi-targeted TKI, was administered to the patient.
- Evaluation of clinical response and mast cell mediator control.
Main Results:
- Sunitinib demonstrated efficacy in controlling mast cell activation and mediator release.
- The treatment was successful in a patient with systemic mastocytosis.
- This represents the first documented use of sunitinib for this condition.
Conclusions:
- Sunitinib is a potential therapeutic option for systemic mastocytosis.
- Further research is warranted to explore sunitinib's role in mast cell activation diseases.
- Targeted therapies like sunitinib may offer new avenues for treating systemic mastocytosis.
More Related Videos
Related Concept Videos
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Second Order systems II
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
First Order Systems
When a first-order system is subjected to a unit-step input, its response is characterized by its transfer function. By applying the Laplace transform of the unit-step input to the transfer function, expanding the...
Second Order systems I
By reinterpreting the system, one can derive the closed-loop transfer function, which...

